| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Product revenue, net | 390 | NaN | ||
| Cost of sales | 20 | 345 | ||
| Amortization of intangible asset | 349 | NaN | ||
| Research and development | 1,261 | 1,000 | ||
| General and administrative | NaN | 4,184 | ||
| Selling, general and administrative | 6,491 | NaN | ||
| Total operating expenses | 8,121 | 5,529 | ||
| Operating loss | -7,731 | -5,529 | ||
| Interest expense, net | -441 | -316 | ||
| Adjustments to fair value of derivatives | -673 | -585 | ||
| Other expense, net | -2 | -20 | ||
| Total other expense | -1,116 | -921 | ||
| Loss before income taxes | -8,847 | -6,450 | ||
| Income tax expense | 132 | 59 | ||
| Net loss | -8,979 | -6,509 | ||
| Basic EPS | -0.2 | -0.16 | ||
| Diluted EPS | -0.2 | -0.16 | ||
| Basic Average Shares | 45,801,927 | 39,935,213 | ||
| Diluted Average Shares | 45,801,927 | 39,935,213 | ||
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)